In last trading session, Graphite Bio Inc. (NASDAQ:GRPH) saw 0.42 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $16.71 trading at $0.32 or 1.95% at ring of the bell on the day assigns it a market valuation of $990.90M. That closing price of GRPH’s stock is at a discount of -103.47% from its 52-week high price of $34.00 and is indicating a premium of 9.93% from its 52-week low price of $15.05. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.25 million shares which gives us an average trading volume of 348.18K if we extend that period to 3-months.
For Graphite Bio Inc. (GRPH), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.50. Splitting up the data highlights that, out of 4 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 4 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.3 in the current quarter.
Graphite Bio Inc. (NASDAQ:GRPH) trade information
Upright in the green during last session for gaining 1.95%, in the last five days GRPH remained trading in the green while hitting it’s week-highest on Wednesday, 09/29/21 when the stock touched $16.71 price level, adding 2.45% to its value on the day. Graphite Bio Inc.’s shares saw a change of -9.68% in year-to-date performance and have moved 0.24% in past 5-day. Graphite Bio Inc. (NASDAQ:GRPH) showed a performance of -14.88% in past 30-days. Number of shares sold short was 2.72 million shares which calculate 10.13 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $34.67 to the stock, which implies a rise of 51.8% to its current value. Analysts have been projecting $34.00 as a low price target for the stock while placing it at a high target of $35.00. It follows that stock’s current price would drop -109.46% in reaching the projected high whereas dropping to the targeted low would mean a loss of -103.47% for stock’s current value.
Graphite Bio Inc. is more likely to be releasing its next quarterly report in November and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Graphite Bio Inc. (NASDAQ:GRPH)’s Major holders
Insiders are in possession of 9.51% of company’s total shares while institution are holding 79.89 percent of that, with stock having share float percentage of 88.29%. Investors also watch the number of corporate investors in a company very closely, which is 79.89% institutions for Graphite Bio Inc. that are currently holding shares of the company. Samsara BioCapital, LLC is the top institutional holder at GRPH for having 7.43 million shares of worth $228.37 million. And as of Jun 29, 2021, it was holding 12.80% of the company’s outstanding shares.
The second largest institutional holder is FMR, LLC, which was holding about 3.76 million shares on Jun 29, 2021. The number of shares represents firm’s hold over 6.48% of outstanding shares, having a total worth of $115.61 million.
On the other hand, Fidelity Select Portfolios – Health Care and Fidelity Advisor Health Care Fund are the top two Mutual Funds which own company’s shares. As of Jul 30, 2021, the former fund manager was holding 0.5 million shares of worth $10.68 million or 0.86% of the total outstanding shares. The later fund manager was in possession of 0.4 million shares on Jul 30, 2021, making its stake of worth around $8.54 million in the company or a holder of 0.69% of company’s stock.